ArticleMicrosystems & nanoengineering2026
Extreme sensitivity label-free biosensing platform based on topologically disruptive phase nano-optics.
Article in Microsystems & nanoengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Strategies for Multiplexing Plasmonic Biosensing.Sensors (Basel, Switzerland) · 2026Review
- Recent Progress in Artificial Intelligence in Biosensor Development: From Bioprobe Design to Fabrication and Signal Analysis.Biosensors · 2026Review
- Capillary-Driven Microfluidic Electrical Screening of Influenza H3N2-Infected A549 Cells Using AgNP-Decorated Laser-Patterned Villous Microstructures.Biosensors · 2026Article
- Nano-Enabled Microfluidic Platforms for Functional Immunomonitoring in Pediatric Sepsis.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Label-free plasmonic biosensors hold significant promise for advancing molecular biology research and enabling early disease diagnostics, particularly in detecting trace amounts of target molecules in highly diluted solutions. However, conventional plasmonic biosensors face substantial challenges in detecting lower-molecule-weight (<500 Da) biomolecules, especially at extreme low concentrations. To overcome this limitation, a novel plasmonic biosensor platform based on enhanced topological phase singularity has been proposed. Herein, we demonstrate that extremely small-sized (<3 nm) silver nanoparticles, embedded in aluminum oxide with a highly ordered configuration and sub-nanometer alignment and inter-particle spacing (<1 nm), and covered by a gold film, exhibit a topologically dark reflection and produces a sharp phase change, which ultimately presents as a significant shift in the reflected beam's position. By precisely modulating the concentration of silver nanoparticles, a largest position shift of 554.3 µm was achieved in calibration experiments with an extreme sensitivity of 3.27 × 10
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.